Rising Chronic Portfolio to Improve Growth Quality: The company is progressively increasing its penetration of specialty chronic therapies namely cardiology and diabetes. The pivot to chronic therapies would further add to stability in revenues, operating margins, and long-term earnings power on account of high repeat nature of chronic segment prescription and greater brand stickiness. BSV Acquisition Strengthens Specialty Business: Purchase of BSV bolstered the specialty business and led to a significant leap in women's...